CD19: The Core Marker of B Cells and a Revolutionary Target in Disease Treatment
Author: Senior Product Manager of UA Views：1219 
The CD19 protein is a transmembrane protein specifically expressed in the B-cell lineage, playing a critical role in B-cell development, activation, and signal transduction.
- Recent Advances
- Product Information
Recent Advances
CD19 is a transmembrane protein specifically expressed in the B-cell lineage, playing a pivotal role in B-cell development, activation, and signal transduction. As the most stable surface marker of B cells, CD19 is not only indispensable in the diagnosis and classification of B-cell malignancies but has also become a core target for autoimmune disease treatment and revolutionary cell therapies such as CAR-T. This article systematically elucidates the central value of CD19 in biomedical research and clinical practice from four dimensions: molecular structure, biological function, disease association, and translational applications.
I. Molecular Analysis: What is CD19?
1.1 Structural and Expression Characteristics
CD19 is a type I transmembrane glycoprotein with a molecular weight of approximately 95 kDa, encoded by the human CD19 gene.
Domains: Its extracellular region contains two immunoglobulin-like domains (C2-type), responsible for ligand binding; the intracellular region is longer, containing multiple conserved tyrosine phosphorylation sites that recruit downstream signaling molecules.
Expression profile: It is stably expressed throughout all developmental stages of B cells, from early precursors to mature B cells, but is lost upon terminal differentiation into plasma cells. It is also expressed on follicular dendritic cells. This nearly "exclusive" expression pattern makes it the "identity card" of B cells.
Domains: Its extracellular region contains two immunoglobulin-like domains (C2-type), responsible for ligand binding; the intracellular region is longer, containing multiple conserved tyrosine phosphorylation sites that recruit downstream signaling molecules.
Expression profile: It is stably expressed throughout all developmental stages of B cells, from early precursors to mature B cells, but is lost upon terminal differentiation into plasma cells. It is also expressed on follicular dendritic cells. This nearly "exclusive" expression pattern makes it the "identity card" of B cells.
1.2 Biological Function: The "Co-Receptor Amplifier" of B-Cell Signaling
CD19 does not function independently but forms the B-cell co-receptor complex with CD21 (complement receptor 2), CD81, and Leu-13.
Signal amplification: When the B-cell receptor (BCR) recognizes an antigen, the co-receptor complex can simultaneously bind complement fragment C3d-coated antigens, amplifying the signal 10- to 1000-fold and significantly lowering the activation threshold of B cells.
Regulation of development and differentiation: By modulating BCR signal strength, it influences B-cell developmental selection (negative/positive selection) in the bone marrow and the maintenance of peripheral immune tolerance.
Memory B-cell generation: It is crucial for germinal center reactions and the formation of long-lived memory B cells.
Signal amplification: When the B-cell receptor (BCR) recognizes an antigen, the co-receptor complex can simultaneously bind complement fragment C3d-coated antigens, amplifying the signal 10- to 1000-fold and significantly lowering the activation threshold of B cells.
Regulation of development and differentiation: By modulating BCR signal strength, it influences B-cell developmental selection (negative/positive selection) in the bone marrow and the maintenance of peripheral immune tolerance.
Memory B-cell generation: It is crucial for germinal center reactions and the formation of long-lived memory B cells.
II. Core Disease Associations: CD19 as a "Pathological Marker" and "Therapeutic Window"
The normal function of CD19 maintains humoral immune balance, while its abnormalities are closely linked to various diseases.
2.1 B-Cell Malignancies (Core Associated Field)
Nearly all B-cell-derived hematologic tumors highly express CD19, making it the primary target for diagnosis and treatment.
Acute B-lymphoblastic leukemia (B-ALL): >90% of patients' leukemic cells express CD19, making it the gold standard for immunophenotyping and a major indication for CAR-T therapy.
Diffuse large B-cell lymphoma (DLBCL) and other non-Hodgkin B-cell lymphomas: CD19 is a core marker for pathological diagnosis and stratification.
Chronic lymphocytic leukemia (CLL): Although expression levels may be lower, CD19 remains a critical diagnostic marker.
Acute B-lymphoblastic leukemia (B-ALL): >90% of patients' leukemic cells express CD19, making it the gold standard for immunophenotyping and a major indication for CAR-T therapy.
Diffuse large B-cell lymphoma (DLBCL) and other non-Hodgkin B-cell lymphomas: CD19 is a core marker for pathological diagnosis and stratification.
Chronic lymphocytic leukemia (CLL): Although expression levels may be lower, CD19 remains a critical diagnostic marker.
2.2 Autoimmune Diseases
Pathogenic autoreactive B cells are central drivers of many autoimmune diseases.
Systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), etc.: Patients harbor activated autoreactive B-cell subsets, and targeting CD19 can eliminate these pathogenic cells to treat the diseases. For example, CD19 CAR-T therapy has shown potential for deep remission in refractory SLE.
Systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), etc.: Patients harbor activated autoreactive B-cell subsets, and targeting CD19 can eliminate these pathogenic cells to treat the diseases. For example, CD19 CAR-T therapy has shown potential for deep remission in refractory SLE.
2.3 Immunodeficiency Diseases
Rare congenital immunodeficiency diseases associated with CD19 gene mutations manifest as impaired antibody production and increased susceptibility to infections.
III. Translational Applications: From Diagnosis to Treatment
3.1 Diagnosis and Monitoring
Flow cytometry immunophenotyping: CD19 antibodies (often combined with CD20, CD10, CD5, etc.) are cornerstone reagents for diagnosing and monitoring B-cell leukemias.
Immunohistochemistry: Confirms B-cell origin in lymphoma tissue sections.
Minimal residual disease (MRD) monitoring: Uses high-sensitivity flow cytometry to detect residual CD19-positive malignant cells post-treatment, which is critical for assessing efficacy and predicting relapse.
Immunohistochemistry: Confirms B-cell origin in lymphoma tissue sections.
Minimal residual disease (MRD) monitoring: Uses high-sensitivity flow cytometry to detect residual CD19-positive malignant cells post-treatment, which is critical for assessing efficacy and predicting relapse.
3.2 Revolutionary Therapeutic Targets
The success of CD19 lies in its dual role as both a diagnostic marker and an ideal therapeutic entry point.
CAR-T cell therapy: This is the most prominent application of CD19. By genetically engineering patient T cells to express chimeric antigen receptors (CARs) targeting CD19, they precisely kill CD19-positive B-cell tumors. Drugs like Axicabtagene ciloleucel (Yescarta) and Tisagenlecleucel (Kymriah) are approved for relapsed/refractory B-ALL and DLBCL.
Antibody-drug conjugates (ADCs): Such as Loncastuximab tesirine, which couples anti-CD19 monoclonal antibodies with cytotoxic agents for targeted delivery, approved for DLBCL.
Bispecific antibodies: Like Blinatumomab, which simultaneously binds T cells (CD3) and tumor cells (CD19), redirecting T-cell cytotoxicity—a key drug for B-ALL.
Monoclonal antibodies: Naked antibodies directly targeting CD19 are also in clinical development.
CAR-T cell therapy: This is the most prominent application of CD19. By genetically engineering patient T cells to express chimeric antigen receptors (CARs) targeting CD19, they precisely kill CD19-positive B-cell tumors. Drugs like Axicabtagene ciloleucel (Yescarta) and Tisagenlecleucel (Kymriah) are approved for relapsed/refractory B-ALL and DLBCL.
Antibody-drug conjugates (ADCs): Such as Loncastuximab tesirine, which couples anti-CD19 monoclonal antibodies with cytotoxic agents for targeted delivery, approved for DLBCL.
Bispecific antibodies: Like Blinatumomab, which simultaneously binds T cells (CD3) and tumor cells (CD19), redirecting T-cell cytotoxicity—a key drug for B-ALL.
Monoclonal antibodies: Naked antibodies directly targeting CD19 are also in clinical development.
IV. Challenges and Future Perspectives
4.1 Current Challenges
Antigen loss post-targeted therapy: Some patients experience tumor cell escape via CD19 downregulation or splice variants after CD19 CAR-T or antibody therapy, leading to relapse.
B-cell depletion: Treatments can chronically deplete normal B cells, causing hypogammaglobulinemia, necessitating regular immunoglobulin infusions to prevent infections.
B-cell depletion: Treatments can chronically deplete normal B cells, causing hypogammaglobulinemia, necessitating regular immunoglobulin infusions to prevent infections.
4.2 Cutting-Edge Directions
Combined/sequential targeting strategies: Developing dual-target (e.g., CD19/CD20, CD19/CD22) CAR-T or sequential therapies to reduce antigen escape risk.
Universal CAR-T (UCAR-T): Using healthy donor T cells to prepare "off-the-shelf" products, reducing costs and wait times.
Safety switches and controllability: Incorporating inducible "suicide switches" or regulatory elements into CARs to manage toxicities like cytokine release syndrome.
Expansion into autoimmune diseases: CAR-T therapy is rapidly extending from oncology to autoimmune diseases like SLE, potentially enabling "functional cures."
Universal CAR-T (UCAR-T): Using healthy donor T cells to prepare "off-the-shelf" products, reducing costs and wait times.
Safety switches and controllability: Incorporating inducible "suicide switches" or regulatory elements into CARs to manage toxicities like cytokine release syndrome.
Expansion into autoimmune diseases: CAR-T therapy is rapidly extending from oncology to autoimmune diseases like SLE, potentially enabling "functional cures."
Conclusion
From a basic B-cell differentiation antigen, CD19 has evolved into a paradigm molecule bridging basic immunology, clinical diagnosis, and cutting-edge therapy. It is not only a window into understanding B-cell biology and disease mechanisms but has also catalyzed revolutions like CAR-T in tumor immunotherapy. As knowledge of its functional mechanisms, resistance, and escape deepens, and as engineering technologies continue to advance, CD19-targeted strategies will keep transforming treatment paradigms for hematologic malignancies and autoimmune diseases, bringing hope to more patients.
This article is reviewed and published by the technical expert team of UA
Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.
Purchase recombinant protein, choose Nanjing UA-Bio
UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.
Target proteins | membrane proteins | cytokines | enzymes | viral antigens | protein customization
Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161
Product Information
Link：
©2021-2026 all rights reserved UA Biotechnology Co.,Ltd.
Privacy Policy 
网站备案号 浙ICP备2022019033号-2 浙公网安备33010202004867号
Business license (three certificates in one) Tel：+86-25-56221161
E-mail：order@ua-bio.com
All products sold on this website shall not be used for clinical diagnosis or treatment of humans or animals, and shall only be used for non-medical purposes such as industrial or scientific research.
